Ph.D. Jay R. Luly - 12 Feb 2025 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Signature
/s/ Matthew Kowalsky as attorney-in-fact
Issuer symbol
ENTA
Transactions as of
12 Feb 2025
Net transactions value
-$41,836
Form type
4
Filing time
14 Feb 2025, 16:35:58 UTC
Previous filing
10 Dec 2024
Next filing
26 Nov 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Award $0 +25,500 +3% $0.000000 872,138 12 Feb 2025 Direct F1
transaction ENTA Common Stock Tax liability $41,836 -7,484 -0.86% $5.59 864,654 12 Feb 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025.
F2 Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards.